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A very simple and convenient one-pot synthesis of spiro-3,4-dihydro-2H-pyrrole has been developed while synthesising 
the 2,2,5-trisubstituted pyrrolidines. Initially, the Meldrum’s acid has been treated with ,-unsaturated ketones in presence 
of anhydrous carbonate base and phase transfer catalyst benzyltriethylammonium chloride in acetonitrile to afford the 
Michael adduct which is readily converted to the corresponding oxime using standard conditions. The crude oxime is treated 
directly with p-toluenesulfonyl chloride and in presence of excess organic base results in tandem nucleophilic cyclisation 
product spirobicyclic as spiro-3,4-dihydro-2H-pyrrole directly, instead the tosyloxime as product. 
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The substituted Pyrroles are the most important and 
explored heterocyclic compounds as they are found in 
many natural products and biologically active 
compounds1-3 as well are privileged scaffolds for 
pharmaceutical products4-8 since they exhibit a diverse 
range of biological activities, including analgesic, 
anti-convulsant, anti-depressant, anti-allergic,  
anti-diabetic, anti-hyperlipidemic, anti-microbial, 
anti-fungal, anti-viral, anti-inflammatory, cholesterol-
reducing, and anti-tumor properties9-12. Therefore, 
substituted pyrroles are considered as a potential 
source of biologically active compounds with 
valuable properties. 
The Spiro heterocyclic compounds are considered 
as a privileged framework because of its rigidity, 
three-dimensional geometries, and wide distribution 
in various natural products and synthetic molecules. 
Presently, these Spiro-heterobicycles compounds are 
attracting considerable interest in synthetic organic 
chemistry because of its molecular structure and 
diverse biological activities13. In addition, spiro-
heterocycle systems impart structural novelty for drug 
discovery because of its broad range of medicinal 
properties14-18, as well important structural motifs that 
are entrenched in a variety of drugs, including the 
cardiovascular active Irbesartan19,20, progestogenic 
agent Drospirenone21,22 and potassium-separating 
diuretic Spironolactone23,24. The normally used 
approach in the drug designing is to rigidify the ligand 
conformation by a spiro-ring fusion, which can 
impact ligand binding entropy upon binding to a 
protein target. Commonly, bioactive spirocyclic 
molecules contain five membered ring systems in 
their structures. In particular, spiro-pyrroles represent 
important structural motifs that can be found in many 
biologically active synthetic compounds and natural 
products25,26. We have recently reported that, under 
basic conditions, tosyloxime of Michael adduct with 
diethyl malonate results in the cyclization with 
C-N bond formation to pyrrolidine embedded with
varies functionality27,28. In similar line to introduced
the rigidity, we have used Meldrum’s acid as source
of nucleophile in Michael addition with different ,
-unsaturated ketones which on oximation and
followed by tosylation in excess of basic condition
results into the Spiro-3,4-dihydro-2H-pyrrole in good
yield as one pot synthesis.
Result and Discussion 
Spiro-heterobicycles appear in countless natural 
products and clinically valuable compounds29 
possibly among the most challenging structural motifs 
to synthesise, spirocyclic synthesis has inspired 
chemists for decades. Meldrum’s acid appears to be 
an attractive reagent in organic synthesis owing to its 
high acidity, steric rigidity and high reactivity30. 
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Following the methodology developed27 using oxime 
ether mediated ring closure, Meldrum’s acid could be 
very useful to synthesise spiro-heterobicyclic rings. 
Indeed, the spiro-heterobicycle 3 could be helpful to 
construct non natural amino acid by solvolysis of 
Meldrum’s acid with alcohols would give a 
diastereomeric mixture of a half acid ester; and there 
could be further interconverted. The half carboxylic 
acid can be converted into amine or carbamate, 
through acid azide formation, and followed by Curtius 
rearrangement, would give an isocyanate, which 
could be easily converted into amine or carbamate by 
hydrolysis or alcohol treatment31. 
The required spiro-heterobicyclic ring 3 could be 
synthesised by following the sequence of reactions. 
The reaction of Meldrum’s acid with methyl vinyl 
ketone in presence of 1.1 eq. of anhydrous K2CO3 and 
1 eq. of benzyltriethylammonium chloride in 
acetonitrile as the solvent, at 50-60°C for 8-10 h32 
afforded the Michael adduct 1 in 81% yield with some 
double Michael addition product as by-product which 
was minimised by using 1.1eq. base. The Michael 
adduct 1 was readily converted to the corresponding 
oxime using standard conditions (NH2OH.HCl and 
Et3N in EtOH stirred at 50°C for 1 hr) and afforded 2 
in 77% yield. The crude oxime 2 was used directly 
and treatment with p-toluenesulfonyl chloride and 
base (excess Et3N in dry CH2Cl2 at RT) gave the 
cyclization product Spiro-3,4-dihydro-2H-pyrrole 3 
directly in 78% of yield (Scheme I) instead the 
expected tosyl oxime (Scheme I). 
The resultant Spiro-3,4-dihydro-2H-pyrrole 3 is 
crystalline and this product was fully characterised by 
single-crystal X-ray crystallographic analysis 
(Figure 1), clearly demonstrating the fully orthogonal 
nature of the two heterocyclic rings. The spiro-
heterobicycle 3 was previously reported by 
Danheiser33 and he obtained as oil but NMR 
data agree. 
Similarly the Michael addition reaction with 
Meldrum’s acid and ,-unsaturated ketones such as 
1-phenylbut-2-en-1-one, 1-phenylprop-2-en-1-one,
pent-3-en-2-one and chalcone was carried out in
presence of anhydrous K2CO3 and 1 eq. of
benzyltriethylammonium chloride in acetonitrile as
the solvent, at 50-60°C for 8-10 hr except chalcone
other ketones gave good yield as Michael adduct as
shown in Scheme II. The same Michael adduct on
oximation using standard condition and followed by
treatment with p-toluenesulfonyl chloride and base
(excess Et3N in dry CH2Cl2 at RT) gave the
cyclization product Spiro-3,4-dihydro-2H-pyrrole as
6, 9 and 12 in good yield as shown in Scheme II but
as the compounds are solid but the formation of single
crystal was so difficult and all compounds are
characterised by Mass and NMR spectra.
Experimental Section 
General procedure for the preparation of Michael 
adduct 9-12 
To a stirring solution 7.63 mmol of Meldrumic acid 
(1.1g) in acetonitrile (20 mL) was added 8.39 mmol 
Scheme I 
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of anhydrous K2CO3 (1.15g) and 7.63 mmol of 
benzyltriethylammonium chloride (1.73g). The 
mixture was stirred for 15 min at RT and 7.63 mmol 
of methyl vinyl ketone (0.64mL) was then added and 
the resultant mixture was stirred for 8 hr at 50°C. 
After TLC monitored, the mixture was cooled to RT, 
the reaction was quenched with water and mixture 
was washed with diethyl ether and then acidified by 6 
N HCl. The adduct was extracted by diethyl ether and 
dried over Na2SO4, to give crude product, which was 
purified by recrystallization using EtOAc and 
petroleum ether to afford Michael adduct 1. 
General procedure for the preparation of oxime of 
Michael adduct 27,28 
To the solution of 2.33 mmol Michael adduct 
ketone 1 (500mg) in 10 mL EtOH was added 4.66 
mmol of NH2OH·HCl (183mg) and 4.66 mmol of 
Et3N (470mg) and the reaction mixture was heated to 
50°C for 1 hr. The progress of the reaction was 
monitored by TLC and on completion of the reaction 
mixture was allowed to cool to RT. EtOH was 
removed under reduced pressure and the residue was 
dissolved in EtOAc and H2O added. The organic layer 
was separated, washed with brine and dried over 
Na2SO4. Concentration of the organic layer gave the 
crude product, which was purified by flash column 
chromatography (eluting with EtOAc : petrol) to 
afford the oxime product 2. 
General procedure for cyclization to spiro-3,4-
dihydro-2H-pyrrole 29 
The stirring solution 2.18 mmol of 2 oxime 
(500mg) in dry 10 mL CH2Cl2 at 0°C was treated with 
6.54 mmol of Et3N or pyridine (660mg or 516mg) 
followed by slow addition 2.61 mmol of p-
toluenesulphonyl chloride (494 mg) and reaction was 
stirred for 1 hrs and it was found in mass spectra 
showed presence of cyclized product. The reaction 
mixture was further stirred for 2 hrs and the reaction 
progress was monitored by TLC and by mass spectra 
and it was found that instead of tosyloxime the 
cyclized product was formed and after completion of 
reaction (1 M) HCl was added and product was 
extracted by CH2Cl2 and the extracts were washed 
with saturated NaHCO3 and dried over Na2SO4. 
Concentration of CH2Cl2 gave crude product which 
was purified by flash column chromatography 




Following the general procedure 1, to the stirring 
solution 15.3 mmol of Meldrumic acid (2.21g) in 
Figure 1 — X-ray crystal structure for spiro-3,4-dihydro-2H-
pyrrole 3 
Scheme II 




acetonitrile (40 mL) was added 16.8 mmol of 
anhydrous K2CO3 (2.31g) and 15.3 mmol of 
benzyltriethylammonium chloride (3.48g). The 
mixture was stirred for 15 min at RT and 15.3 mmol 
of methyl vinyl ketone (1.3mL) was then added and 
the resultant mixture was stirred for 8 hr at 50°C to 
give crude product, which was purified by 
recrystallization using EtOAc and petroleum ether to 
afford adduct 1 (2.67 g, 81%) as pale yellow solid 
(m.p.116-118°C, lit 119-120°C); Rf = 0.16 (EtOAc : 
petrol, 1:1); IR (film): 2892, 1785, 1747, 1710, 1382, 
1303, 1249, 1165, 1010, 986, 730 cm−1; 1H NMR: 
δH(400 MHz; CDCl3; Me4Si) 1.74, 1.78 (6H, s, 
C(CH3)2), 2.13 (3H, s, COCH3), 2.78 (2H, m, 
CH2CH2CH), 2.75 (2H, t, J 7.1 Hz, CH2CH2CH), 3.86 
(1H, t, J 5.4 Hz, CH2CH2CH); 
13C NMR: δC(100 
MHz; CDCl3; Me4Si) 19.5 (CH2CH2CH), 25.8, 27.9 
C(CH3)2), 29.5 (COCH3), 38.7 (CH2CH2CH), 44.0 
(CH2CH2CH), 104.5 (C(CH3)2), 164.7 (2 × COO), 
207.5 (CO); MS (ESI−): m/z 213, ([M-H]−, 100%); 
HRMS (ESI−) C10H13O5




ane-4,6-dione, 2 27,28 
Following the general procedure 2, to the solution 
6.44 mmol of Michael adduct 1 (1.38 g) in EtOH 
(30mL), 12.88 mmol of NH2OH.HCl (888mg,) and 
12.88 mmol of Et3N (1.30g) was added and the 
mixture was gently heated (50°C) for 1 hrs, to give 
crude product which was purified by flash column 
chromatography to afford oxime 2 (1.14 g, 77%) as 
pale yellow semi-solid; Rf = 0.23 (EtOAc : petrol, 
1:1); IR (film): 3319, 2982, 1786, 1743, 1715, 1372, 
1307, 1240, 1176, 1012, 982, 731 cm−1; 1H NMR: 
(major isomer) δH(400 MHz; CDCl3; Me4Si) 1.74, 
1.78 (6H, s, C(CH3)2), 1.94, 1.91 (3H, s, CNOHCH3), 
2.31 (2H, m, CH2CH2CH), 2.44, 2.63 (2H, t, J 7.4 Hz, 
CH2CH2CH), 3.68 (1H, t, J 6.8 Hz, CH2CH2CH), 9.33 
(1H, bs, OH); 13C NMR: δC(100 MHz; CDCl3; Me4Si) 
13.9, 15.1 (CNOHCH3), 21.3, 22.1 (CH2CH2CH), 
26.2, 27.3 (C(CH3)2), 32.2, 35.9 (CH2CH2CH), 44.8 
(CH2CH2CH), 104.8, 106.1 (C(CH3)2), 157.6, 158.1 
(C=NOH), 162.7, 164.9 (2 × COO); MS (ESI−): m/z 
228 ([M-H]−, 100%); HRMS (ESI−) C10H14NO5
− ([M-
H]−) requires: 228.0881. Found: 228.0877. 
 
(±) 2,8,8-Trimethyl-7,9-dioxa-1-azaspiro[4.5]dec-1-
ene-6,10-dione, 3 34,35 
Following the general procedure 3, to the solution 
1.79 mmol of oxime 2 (412mg) in dry CH2Cl2 (20mL) 
was added 5.37 mmol of Et3N (542mg) at 0°C and 
followed by 2.15 mol of p-toluenesulphonyl chloride 
(410 mg) and the mixture stirred for 30 min instead 
tosyl oxime, isolated cyclized product as spirobicyclic 
pyrrolidine which was purified by flash column 
chromatography to afford compound 3 (297 mg, 78%) 
as a crystalline solid; m.p. = 98C; Rf = 0.63 (EtOAc : 
petrol, 1:1); IR (film): 2933, 1782, 1731, 1452, 1170, 
914, 731 cm−1; 1H NMR (400 MHz; CDCl3; Me4Si): 
δH 1.78, 2.06 (C(CH3)2), 2.16 (3H, s, N=CCH3), 2.59 
(2H, t, J 7.6 Hz, C(4)HH), 2.97 (2H, t, J 7.6 Hz, 
C(3)HH); 13C NMR (100 MHz; CDCl3; Me4Si): δC 
19.2 (COCH3), 28.3, 28.5 C(CH3)2), 31.4 (C4), 41.2 
(C3), 80.7 (C2), 106.2 C(CH3)2), 167.4 (2 × COO), 
182.9 (C5); MS (ESI−): m/z 445 ([2M+Na]+, 100%), 
234 ([M+Na]+, 95%); HRMS (ESI+) C10H13NNaO5
+ 




Following the general procedure 3, to the solution 
0.95 mmol of oxime 5 (289 mg) in dry CH2Cl2 (15 
mL) was added 2.85 mmol of Et3N (288mg) at 0°C 
and followed by 1.14 mmol of p-toluenesulphonyl 
chloride (216 mg) and the mixture was stirred for 30 
min instead tosyl oxime, isolated cyclized product as 
spirobicyclic pyrrolidine which was purified by flash 
column chromatography to afford compound 6 (160 
mg, 59%) as a crystalline solid; m.p. = 103C; Rf = 
0.46 (EtOAc : petrol, 1:1.5); IR (film): 3078, 2956, 
1779, 1737, 1170, 912, 740 cm−1; 1H NMR (400 
MHz; CDCl3; Me4Si): δH 0.96 (3H, d, CH3), 1.75, 
2.00 (C(CH3)2), 2.55 (2H, d, J 7.5 Hz, C(4)HH), 2.79 
(1H, m, C(3)H), 7.3-7.9 (ArH); 13C NMR (100 MHz; 
CDCl3; Me4Si): δC 28.9, 28.2 C(CH3)2), 31.9 (C4), 
41.0 (C3), 89.7 (C5), 106.0 C(CH3)2), 112-139 (ArC), 
167.0 (2 × COO), 180.9 (C2); MS (ESI−): m/z 310 
([M+Na]+, 95%); HRMS (ESI+) C16H17NNaO4
+ 
([M+Na]+) requires: 310.1055. Found: 234.1076. 
 
(±) 8,8-Dimethyl-2-phenyl-7,9-dioxa-1-azaspiro [4.5] 
dec-1-ene-6,10-dione, 9 
Following the general procedure 3, to the solution 
0.69 mmol of oxime 8 (200mg) in dry CH2Cl2 (10mL) 
was added 2.07 mmol of Et3N (209mg) at 0°C and 
followed by 0.83 mmol of p-toluenesulphonyl 
chloride (157 mg,) and mixture was stirred for 30 min 
instead tosyl oxime, isolated cyclized product as 
spirobicyclic pyrrolidine which was purified by flash 
column chromatography to afford compound 9  
(120 mg, 64%) as a crystalline solid; m.p. = 97C;  




Rf = 0.53 (EtOAc : petrol, 1:1); IR (film): 3093, 2931, 
1778, 1735, 1177, 910 cm−1; 1H NMR (400 MHz; 
CDCl3; Me4Si): δH 1.70, 2.03 (C(CH3)2), 2.52 (2H, t,  
J 7.4 Hz, C(4)HH), 2.90 (2H, t, J 7.4 Hz, C(3)HH), 
7.3-7.9 (ArH); 13C NMR (100 MHz; CDCl3; Me4Si): 
δC 28.9, 28.2 C(CH3)2), 31.9 (C4), 41.0 (C3),  
89.7 (C5), 106.0 C(CH3)2), 114-138 (ArC), 167.0  
(2 × COO), 180.9 (C2); MS (ESI−): m/z 296 
([M+Na]+, 95%); HRMS (ESI+) C15H15NNaO4
+ 
([M+Na]+) requires: 296.0899. Found: 234.0901. 
 
(±) 2,4,8,8-Tetramethyl-7,9-dioxa-1-azaspiro[4.5] dec 
-1-ene-6,10-dione, 12 
Following the general procedure 3, to the solution 
0.88 mmol of oxime 11 (215mg) in dry CH2Cl2 
(10mL) was added 2.64 mmol of Et3N (267mg)  
at 0°C and followed by 1.06 mmol of  
p-toluenesulphonyl chloride (201 mg,) and the 
mixture stirred for 30 min instead tosyl oxime, 
isolated cyclized product as spirobicyclic pyrrolidine 
which was purified by flash column chromatography 
to afford compound 12 (111 mg, 56%) as a crystalline 
solid; m.p. = 99C; Rf = 0.51 (EtOAc : petrol, 1:1); IR 
(film) 2934, 1780, 1732, 1456, 1172, 915, 735 cm−1; 
1H NMR (400 MHz; CDCl3; Me4Si): δH 0.98 (3H, d, 
CH3), 1.79, 2.05 (C(CH3)2), 2.16 (3H, s, N=CCH3), 
2.64 (1H, m, C(4)H), 2.94 (2H, d, J 7.5 Hz, C(3)HH); 
13C NMR (100 MHz; CDCl3; Me4Si): δC 18.2, (CH3), 
21.5 (N=CCH3), 28.4, 28.7 C(CH3)2), 32.1 (C4), 43.2 
(C3), 88.9 (C5), 106.7 C(CH3)2), 167.9 (2 × COO), 
182.8 (C2); MS (ESI−): m/z 248 ([M+Na]+, 95%); 
HRMS (ESI+) C11H15NNaO4
+ ([M+Na]+) requires: 
248.0899. Found: 234.0839. 
 
Conclusion 
In summary, we have developed a one-pot 
methodology for the synthesis of spiro-heterobicyclic 
compounds as spiro-3,4-dihydro-2H-pyrroles with 
alkyl and aryl substitutions on the five member 
heterocycle. It was also concluded that both aryl 
groups as substitution was not possible as we have 
started with chalcone as starting material and reaction 
did not work. The method is useful for the synthesis 
of the rigid spiro-heterocycle which can also be 
converted to the non-natural amino acids by 
hydrolysis to half acid ester and interconverted to 
amino group through Curtius rearrangement reaction. 
The present methodology developed will be very 
useful to get quick access to spiro-3,4-dihydro-2H-
pyrroles which is are part of many natural products of 
high importance. 
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